CTOs on the Move

Intact Vascular

www.intactvascular.com

 
Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Intact Vascular raised $38M on 05/14/2015
Intact Vascular raised $46M on 01/03/2017
Intact Vascular raised $20M on 04/16/2018
Intact Vascular raised $25M on 05/30/2019

Similar Companies

Poxel

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

SAIC-Frederick

SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MediQuest Therapeutics

MediQuest Therapeutics is a Maple Valley, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cleveland Diagnostics

Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.

Becton Dickinson and Company

Becton Dickinson and Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.